BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38190712)

  • 1. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting.
    Zerbo O; Bartlett J; Fireman B; Lewis N; Goddard K; Dooling K; Duffy J; Glanz J; Naleway A; Donahue JG; Klein NP
    Ann Intern Med; 2024 Feb; 177(2):189-195. PubMed ID: 38190712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
    Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
    Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
    Parikh R; Singer D; Chmielewski-Yee E; Dessart C
    Hum Vaccin Immunother; 2023 Dec; 19(3):2263979. PubMed ID: 37967254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States.
    Florea A; Sy L; Qian L; Ackerson B; Luo Y; Wu J; Cheng Y; Ku J; Vega Daily L; Takhar H; Song J; Chmielewski-Yee E; Spence O; Seifert H; Oraichi D; Tseng HF
    Hum Vaccin Immunother; 2024 Dec; 20(1):2327145. PubMed ID: 38488143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
    Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
    Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
    Lu A; Sun Y; Porco TC; Arnold BF; Acharya NR
    Ophthalmology; 2021 Dec; 128(12):1699-1707. PubMed ID: 33892049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: A retrospective cohort study.
    Sun Y; Jackson K; Dalmon CA; Shapiro BL; Nie S; Wong C; Arnold BF; Porco TC; Acharya NR
    Vaccine; 2021 Jun; 39(29):3974-3982. PubMed ID: 34116874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
    Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records.
    Klein NP; Bartlett J; Fireman B; Marks MA; Hansen J; Lewis E; Aukes L; Saddier P
    BMJ; 2023 Nov; 383():e076321. PubMed ID: 37940142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
    Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
    Stefanizzi P; Moscara L; Palmieri C; Martinelli A; Di Lorenzo A; Venerito V; Germinario CA; Tafuri S
    Vaccine; 2024 Apr; 42(12):2966-2974. PubMed ID: 38582693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
    Giannelos N; Ng C; Curran D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
    Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
    JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study.
    Baxter R; Bartlett J; Fireman B; Marks M; Hansen J; Lewis E; Aukes L; Chen Y; Klein NP; Saddier P
    Am J Epidemiol; 2018 Jan; 187(1):161-169. PubMed ID: 29309521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
    Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes Zoster Vaccines.
    Harbecke R; Cohen JI; Oxman MN
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.